CPT1C and breast cancer: In summary, our findings demonstrate that CPT1C silencing drives PM remodelling, leading, in turn, to DOX chemoresistance in BC cells, and also that low CPT1C expression is a predictive marker of poor survival for anthracycline-based neoadjuvant chemotherapy for patients with HER+ BC and TNBC.